

Recommendations for the use of mpox vaccine

Pan American Health Organization 2025

PAHO



Pan American
Health
Organization



World Health
Organization

Americas Region

Recommendations for the use of mpox vaccine 2025

The Pan American Health Organization (PAHO), with the support of its Strategic Advisory Group on Vaccine-Preventable Diseases, recommends the following on the use of mpox vaccine in the region of the Americas:

1. In keeping with the Strategic Advisory Group of Experts (SAGE) on Immunization guidance, the use of the mpox vaccine in high-risk groups for infection is recommended. The ultimate decision to use the mpox vaccine and in which specific group(s) should be determined by each country based on the epidemiology of the disease in their jurisdiction.
2. The use and improvement of public health measures to reduce transmission of mpox is critical, for example mpox prevention education directed to the high-risk group(s).
3. Countries need to be aware that there is insufficient mpox vaccine available for the global market and, as a result, there will not be enough vaccine to provide coverage for all of their high-risk populations.
4. Careful planning by Member States is crucial to ensuring timely and complete access to vaccines and supplies. This proactive approach helps mitigate delays and shortages, especially during critical times. Additionally, based on the consolidated demand, PAHO would be able to consider implementing advance purchase commitments to address unplanned demands swiftly, enhancing outbreak response capabilities.